30Cердечно-сосудистые заболевания (ССЗ) по-прежнему продолжают занимать лидирующие пози-ции среди причин смертности в Российской Федера-ции. Согласно последним данным, на долю смертно-сти от ишемической болезни сердца (ИБС) приходится 46,8%, что мотивирует ученых и клини-цистов к поиску новых и совершенствованию имею-щихся методов ранней диагностики и эффективного лечения различных форм этой патологии [1].В то же время, все чаще обсуждается проблема метаболического синдрома (МС) и его влияния при полиморбидной патологии. Эксперты Всемирной ОЦЕНКА УРОВНЯ ГАЛЕКТИНА-3 У ПАЦИЕНТОВ С МЕТАБОЛИЧЕСКИМ СИНДРОМОМ И ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА Aim.To assess the level of galectin-3 in blood serum of patients with metabolic syndrome (MS), including comorbidity with coronary heart disease (CHD), for evaluation of its significance as fibrosis marker in MS. material and methods. Totally, 43 MS patients studied with CHD signs, and 33 patients non-MS of comparable age, of those CHD was diagnosed in 17. Mean age in MS group was 62,7±10,3 y. o. at baseline, in controls (non-MS) -60±14,7 y. o. Galectin-3 level was measured via immune-enzyme assay on "Platinum ELISA". Results. Mean level of galectin-3 in MS group was significantly higher and reached 1,89±1,71 ng/mL, comparing to non-MS group -1,03±0,22 ng/mL (р=0,006). There were positive correlations of galectin-3 and CHD functional class by NYHA (r=0,346, р=0,012): in absence of CHD signs galectin-3 level was 1,05±0,26 ng/mL; in CHD of 1 functional class (FC) -1,06±0,18 ng/mL; 2 FC -1,7±1,59 ng/mL; 3 FC -2,15±1,85 ng/mL. Conclusion.The level of fibrosis marker galectin-3 are higher in MS patients than in non-MS, and in MS+CHD is higher than in those without this pathology. Finding of high level of galectin-3 in MS and CHD patients might witness on the severity of myocardial fibrosis, supporting prognosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.